Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where E. Phillips is active.

Publication


Featured researches published by E. Phillips.


International Journal of Cancer | 1999

Location of candidate tumour suppressor gene loci at chromosomes 3p, 8p and 9p for oral squamous cell carcinomas.

Max Partridge; G. Emilion; Stelios Pateromichelakis; E. Phillips; J.D. Langdon

To help define the location of tumour suppressor genes implicated in the pathogenesis of oral squamous cell carcinoma (SCC), we have used microsatellite assay and restriction fragment length polymorphism (RFLP) analysis to screen 48 primary SCC for allelic imbalance (AI) with 32 polymorphic markers at chromosome 3p, and prepared a detailed deletion map. The finding of a high frequency of AI at specific regions, together with the presence of multiple small interstitial deletions involving these loci, identifies 5 areas at this chromosome arm that may harbour tumour suppressor genes. No sequence aberrations affecting the von Hippel Lindau (VHL) and fragile histidine triad (FHIT) genes, which reside within the candidate tumour suppressor gene areas at this chromosome arm, were identified. A more limited analysis of polymorphic sequences at 8p and 9p supports the existence of at least 2 areas that harbour tumour suppressor genes at 8p and evidence that additional targets for deletion reside centromeric and telomeric to the p16 gene at 9p21. Int. J. Cancer 83:318–325, 1999.


The Journal of Pathology | 1999

Immunomagnetic separation for enrichment and sensitive detection of disseminated tumour cells in patients with head and neck SCC.

Max Partridge; E. Phillips; R. Francis; S.-R. Li

Screening for malignant cells in the blood and bone marrow was introduced as a strategy for the improved detection of tumour spread and may predict the development of distant metastases. The sensitivity of these approaches depends on several factors, including the choice of antibody for immunocytochemistry (ICC) and the number of cells examined. In this study criteria have been defined for scoring cells reactive with a pan‐cytokeratin antibody as tumour, by comparing immunostained cells in clinical samples obtained from head and neck cancer patients and a control group without epithelial malignancy. When leucocyte subfractions are prepared by density gradient separation (DGS) from central venous blood obtained from patients with advanced head and neck squamous cell carcinoma (SCC) and screened by ICC, epithelial tumour cells sediment preferentially with the mononuclear cells but may also be detected in the granulocyte (GC) fraction. Some cases were found to have more tumour cells in the GC fraction. Similar results were seen in model experiments. To increase the sensitivity of the ICC approach, the efficiency of positive immunomagnetic selection (IMS) using Dynabeads coated with an antibody recognizing the Ber‐EP4 epitope has been compared with negative IMS using anti‐CD45 Dynabeads. Tumour cells were recovered from bone marrow aspirates for 2/17 cases using the positive enrichment technique and for 11/17 patients following negative IMS. These findings justify prospective studies incorporating negative IMS to establish the prognostic significance of these disseminated tumour cells for this group of patients. Copyright


Cancer Research | 2000

A Case-Control Study Confirms That Microsatellite Assay Can Identify Patients at Risk of Developing Oral Squamous Cell Carcinoma within a Field of Cancerization

Max Partridge; Stylianos Pateromichelakis; E. Phillips; G. Emilion; R P A'Hern; J D Langdon


Clinical Cancer Research | 2000

Detection of Minimal Residual Cancer to Investigate Why Oral Tumors Recur Despite Seemingly Adequate Treatment

Max Partridge; Shu-Rui Li; Stelios Pateromichelakis; Rebecca Francis; E. Phillips; Xiaohong Huang; Fis Tesfa-Selase; John Langdon


Oral Oncology | 1997

Field cancerisation of the oral cavity: comparison of the spectrum of molecular alterations in cases presenting with both dysplastic and malignant lesions.

Max Partridge; G. Emilion; Stelios Pateromichelakis; E. Phillips; J.D. Langdon


Clinical Cancer Research | 2003

Detection of Rare Disseminated Tumor Cells Identifies Head and Neck Cancer Patients at Risk of Treatment Failure

Max Partridge; Ruud H. Brakenhoff; E. Phillips; Kulsan Ali; Rebecca Francis; Richard Hooper; K.M. Lavery; A.E. Brown; John Langdon


Clinical Cancer Research | 2001

Profiling Clonality and Progression in Multiple Premalignant and Malignant Oral Lesions Identifies a Subgroup of Cases with a Distinct Presentation of Squamous Cell Carcinoma

Max Partridge; Stelios Pateromichelakis; E. Phillips; Gracy Emilion; John Langdon


Oral Oncology | 2005

Molecular analysis of paired tumours: Time to start treating the field

Stelios Pateromichelakis; Mosavar Farahani; E. Phillips; Max Partridge


Clinical Cancer Research | 2002

A Preclinical Model of Minimal Residual Cancer in the Muscle Highlights Challenges Associated with Adenovirus-mediated p53 Gene Transfer

Roth Oakley; E. Phillips; Richard Hooper; Deborah Wilson; Max Partridge


Journal of Dental Research | 2004

Clonality Studies in Paired Upper Aerodigestive Tract Tumours

Stylianos Pateromichelakis; M Farahani; E. Phillips; Max Partridge

Collaboration


Dive into the E. Phillips's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

G. Emilion

University of Cambridge

View shared research outputs
Top Co-Authors

Avatar

J.D. Langdon

University of Cambridge

View shared research outputs
Top Co-Authors

Avatar

Richard Hooper

Queen Mary University of London

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

J D Langdon

University of Cambridge

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

R P A'Hern

University of Cambridge

View shared research outputs
Researchain Logo
Decentralizing Knowledge